scPharmaceuticals Inc. (NASDAQ:SCPH) is Worth Venture Partners LLC's 8th Largest Position

Worth Venture Partners LLC increased its stake in scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 42.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 771,344 shares of the company's stock after buying an additional 231,679 shares during the period. scPharmaceuticals accounts for 2.6% of Worth Venture Partners LLC's portfolio, making the stock its 8th largest position. Worth Venture Partners LLC owned approximately 2.15% of scPharmaceuticals worth $4,836,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of SCPH. Raymond James & Associates increased its stake in shares of scPharmaceuticals by 6.6% during the fourth quarter. Raymond James & Associates now owns 87,049 shares of the company's stock valued at $546,000 after purchasing an additional 5,377 shares in the last quarter. Rice Hall James & Associates LLC increased its stake in shares of scPharmaceuticals by 9.1% during the third quarter. Rice Hall James & Associates LLC now owns 87,071 shares of the company's stock valued at $620,000 after purchasing an additional 7,241 shares in the last quarter. Tejara Capital Ltd bought a new position in shares of scPharmaceuticals during the third quarter valued at approximately $722,000. AIGH Capital Management LLC increased its stake in shares of scPharmaceuticals by 7.6% during the third quarter. AIGH Capital Management LLC now owns 2,207,009 shares of the company's stock valued at $15,714,000 after purchasing an additional 155,204 shares in the last quarter. Finally, Rubric Capital Management LP grew its holdings in shares of scPharmaceuticals by 234.3% during the third quarter. Rubric Capital Management LP now owns 2,713,287 shares of the company's stock valued at $19,319,000 after buying an additional 1,901,770 shares during the last quarter. 89.52% of the stock is owned by institutional investors.

scPharmaceuticals Price Performance

Shares of scPharmaceuticals stock traded down $0.71 during trading hours on Monday, reaching $4.04. The company's stock had a trading volume of 564,448 shares, compared to its average volume of 226,385. The firm has a 50 day moving average price of $4.85 and a 200-day moving average price of $5.38. scPharmaceuticals Inc. has a one year low of $4.01 and a one year high of $11.75. The company has a debt-to-equity ratio of 1.60, a current ratio of 6.21 and a quick ratio of 5.44. The stock has a market cap of $145.64 million, a P/E ratio of -2.73 and a beta of 0.09.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. scPharmaceuticals had a negative net margin of 327.29% and a negative return on equity of 132.39%. The firm had revenue of $6.10 million during the quarter, compared to analysts' expectations of $6.50 million. During the same period in the previous year, the company earned ($0.30) EPS. On average, analysts predict that scPharmaceuticals Inc. will post -1.46 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of scPharmaceuticals in a report on Wednesday, May 15th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.

Want to see what other hedge funds are holding SCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.